<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075747</url>
  </required_header>
  <id_info>
    <org_study_id>JZP025-101</org_study_id>
    <nct_id>NCT04075747</nct_id>
  </id_info>
  <brief_title>A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia</brief_title>
  <acronym>V-FAST</acronym>
  <official_title>V-FAST: A Phase 1b Master Trial to Investigate CPX-351 Combined With Various Targeted Agents in Subjects With Previously Untreated Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jazz Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      JZP025-101 is an open-label, multicenter, multi-arm, nonrandomized phase 1b master trial to&#xD;
      determine the recommended phase 2 dose (RP2D) of CPX-351 when administered in combination&#xD;
      with various targeted agents in previously untreated subjects with Acute Myeloid Leukemia&#xD;
      (AML) who are fit to receive intensive chemotherapy (ICT). Subjects will be assigned to&#xD;
      treatment arms based on results of AML mutation testing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>The RP2D will be determined by the specified dose de-escalation/dose escalation algorithm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and Tolerability of CPX-351 and Targeted Agents: incidence of adverse events (AEs) and dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>The safety and tolerability of CPX-351 and targeted agents when given in combination, based on the incidence of adverse events (AEs) and dose limiting toxicities (DLTs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have achieved CR, CRi, CRh, CR + CRi, and CR + CRh</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>After up to 2 inductions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have achieved CR / CRi with MRD negative status</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>After up to 2 inductions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have achieved CR / CRh with MRD negative status</measure>
    <time_frame>Up to 30 months</time_frame>
    <description>After up to 2 inductions</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPX-351</intervention_name>
    <description>Up to 2 induction and 2 consolidation courses will be offered</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>Vyxeos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>Will be administered over specified duration during induction and consolidation courses</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Venclexta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midostaurin</intervention_name>
    <description>Will be administered over specified duration during induction and consolidation courses</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Rydapt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enasidenib</intervention_name>
    <description>Will be administered over specified duration during induction and consolidation courses</description>
    <arm_group_label>Arm C</arm_group_label>
    <other_name>Idhifa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 to ≤ 75 years at the time of informed consent.&#xD;
&#xD;
          -  Newly diagnosed AML according to World Health Organization (WHO) pathological criteria&#xD;
             (with at least 20% blasts in the peripheral blood or bone marrow).&#xD;
&#xD;
          -  ECOG performance status of 0 to 2.&#xD;
&#xD;
          -  Laboratory values fulfilling the following:&#xD;
&#xD;
               -  Serum creatinine &lt; 2.0 mg/dL.&#xD;
&#xD;
               -  Serum total bilirubin &lt; 2.0 mg/dL. (For subjects with Gilbert's Syndrome and&#xD;
                  serum total bilirubin ≥ 2.0 mg/dL, the medical monitor should be contacted.)&#xD;
&#xD;
               -  Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &lt; 3&#xD;
                  times the upper limit of normal (ULN). (Note: If elevated liver enzymes &gt; ULN are&#xD;
                  related to disease, contact medical monitor to discuss.)&#xD;
&#xD;
          -  Cardiac ejection fraction ≥ 50% by echocardiography or multiple gated acquisition scan&#xD;
             (MUGA).&#xD;
&#xD;
          -  Subjects with second malignancies in remission may be eligible if there is clinical&#xD;
             evidence of disease stability for a period &gt; 6 months off cytotoxic chemotherapy,&#xD;
             documented by imaging, tumor marker studies, etc., at screening. Subjects maintained&#xD;
             on long-term nonchemotherapy treatment (eg, hormonal therapy) are eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute promyelocytic leukemia [t(15;17)].&#xD;
&#xD;
          -  Subject has favorable risk cytogenetics ((t8;21), inv(16), t(16;16), or t15;17)&#xD;
             karyotype abnormalities) as categorized by the National Comprehensive Cancer Network&#xD;
             (NCCN) Guidelines Version 2.2014 for AML (NCCN 2014).&#xD;
&#xD;
          -  Clinical evidence of active central nervous system (CNS) leukemia.&#xD;
&#xD;
          -  Subjects with active (uncontrolled, metastatic) second malignancies.&#xD;
&#xD;
          -  Subjects who have received prior treatment intended for induction therapy of AML; only&#xD;
             hydroxyurea is permitted for control of blood cell counts. (For example, a subject&#xD;
             with myelodysplastic syndrome [MDS] who changes hypomethylating agent [HMA] dose and&#xD;
             schedule after the diagnosis of AML is excluded. AML-type therapy, such as cytarabine&#xD;
             alone [&gt; 1g/m2/day] or cytarabine plus an anthracycline as well as prior HSCT are also&#xD;
             excluded.)&#xD;
&#xD;
          -  Subjects receiving administration of any therapy for MDS (conventional or&#xD;
             investigational) must be completed by 2 weeks prior to the first dose of study drug.&#xD;
             In the event of rapidly proliferative disease, use of hydroxyurea is permitted until&#xD;
             24 hours before the start of study treatment. Toxicities associated with prior MDS&#xD;
             therapy must have recovered to Grade 1 or less prior to start of treatment.&#xD;
&#xD;
          -  Subjects with myocardial impairment of any cause (eg, cardiomyopathy, ischemic heart&#xD;
             disease, significant valvular dysfunction, hypertensive heart disease, and congestive&#xD;
             heart failure) resulting in heart failure by New York Heart Association Criteria&#xD;
             (Class III or IV staging).&#xD;
&#xD;
          -  Subjects with active or uncontrolled infection. Subjects with an infection receiving&#xD;
             treatment (antibiotic, antifungal or antiviral treatment) may be entered into the&#xD;
             study but must be afebrile and hemodynamically stable for ≥ 72 hours.&#xD;
&#xD;
          -  Current evidence of invasive fungal infection (blood or tissue culture). Subjects with&#xD;
             recent fungal infection must have a subsequent negative culture to be eligible.&#xD;
&#xD;
          -  Subjects with known human immunodeficiency virus (new testing not required) or&#xD;
             evidence of active hepatitis B or C infection.&#xD;
&#xD;
          -  Subjects with known history of Wilson's disease or other known copper-metabolism&#xD;
             disorder.&#xD;
&#xD;
          -  Subjects with other comorbidity that the investigator judges to be incompatible with&#xD;
             conventional ICT, and / or the targeted agent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Director Clinical Trial Disclosure &amp; Transparency</last_name>
    <phone>2159707145</phone>
    <email>ClinicalTrialDisclosure@JazzPharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine- Standford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center at Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 29, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2019</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
    <mesh_term>Midostaurin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

